{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"57","value":"41"},{"groupId":"OG001","lowerLimit":"23","upperLimit":"49","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"An event is defined as relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacro-MTX/Sirolimus GVHD Prophylaxis","id":"OG000","title":"Experimental"},{"description":"Tacro-MTX GVHD Prophylaxis","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"2 ineligible patients on experimental arm excluded from analysis.Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.","reportingStatus":"POSTED","timeFrame":"At 2 years","title":"Rate of Relapses","type":"SECONDARY","unitOfMeasure":"percentage of participants"}